Drug Sponsors

Water Street invests in generic injectable drug services company Custopharm

Wednesday, February 4, 2015 01:32 PM

Water Street Healthcare Partners, a strategic investor focused exclusively on the healthcare industry headquartered in Chicago, has invested in Custopharm, a generic injectable drug services company. Water Street's team has committed equity to both acquire and expand the Carlsbad, Calif.-based company. The healthcare firm has recruited William Larkins, Ph.D., former vice president and general manager of Bedford Laboratories, as CEO of Custopharm.

More... »


Viropro plans for restructuring following facility seizure

Wednesday, February 4, 2015 01:23 PM

Viropro, an integrated developer and manufacturer of biopharmaceutical products based in San Jose, Calif., has announced that its board of directors completed its strategic review and has begun the implementation of a restructuring designed to restore the company to financial health. 

More... »


OptiKira launched by BioMotiv, UCSF, University of Washington

Wednesday, February 4, 2015 01:18 PM

BioMotiv, a drug development accelerator associated with The Harrington Project, the University of California San Francisco (UCSF) and University of Washington, Seattle, have announced the formation of OptiKira, a platform company that will develop small molecule therapeutics that prevent cell death in pathologies caused by misfolded or unfolded proteins.

More... »

Astellas broadens commitment to clinical trial data transparency

Monday, February 2, 2015 01:57 PM

Astellas Pharma, based in Japan, will now make trial data available through www.clinicalstudydatarequest.com, an independent web site that enables researchers to request and access clinical trial data after approval of a research proposal by an independent review panel.

More... »

Biogen Idec begins 2015 with multiple collaborations

Monday, February 2, 2015 01:45 PM

Biogen Idec left 2014 with cash, cash equivalents and marketable securities totaling approximately $3.3 billion and has begun 2015 with multiple collaborations. The company expects to continue to bolster its R&D capabilities in the coming months.

More... »

Valeant to acquire assets from bankrupt Dendreon

Monday, February 2, 2015 01:41 PM

Valeant Pharmaceuticals International, based in Canada, has entered into a "stalking horse" asset purchase agreement to acquire certain assets of Seattle, Wash.-based biotechnology company Dendreon for $296 million in cash.

More... »

Endo Pharmaceuticals completes acquisition of Auxilium Pharmaceuticals

Monday, February 2, 2015 01:38 PM

Endo International has completed the acquisition of Auxilium Pharmaceuticals in a transaction valued at $2.6 billion. The closing of the transaction, which was announced Oct. 9, 2014, follows approval by Auxilium's shareholders on Jan. 27 and the receipt of all required regulatory approvals.

More... »

AstraZeneca collaborates to use CRISPR technology

Friday, January 30, 2015 12:27 PM

AstraZeneca has announced four research collaborations aimed at harnessing the power of CRISPR, a pioneering genome-editing technique, across its entire discovery platform in the company’s key therapeutic areas. The four research collaborations are with the Wellcome Trust Sanger Institute, Cambridge, U.K.; the Innovative Genomics Initiative, California; Thermo Fisher Scientific, Waltham, Mass.; and the Broad Institute/Whitehead Institute, Cambridge, Mass. The technology will allow AZ to identify and validate new drug targets in preclinical models that closely resemble human disease.

More... »

Regulatory update on GSK-Novartis three-part transaction

Thursday, January 29, 2015 12:25 PM

GlaxoSmithKline has received clearance from the European Commission (E.C.) of its proposed three-part transaction with Novartis, which includes the acquisition of Novartis’s vaccines business (excluding influenza vaccines), the creation of a consumer healthcare joint venture between GSK and Novartis and the divestment to Novartis of GSK’s marketed oncology portfolio, related R&D activities and rights to two pipeline AKT inhibitors.

More... »

3SBio acquires Sirton Pharmaceuticals

Monday, January 26, 2015 02:25 PM

3SBio, a China-based biotechnology company, has acquired the entire share capital of Sirton Pharmaceuticals, located in Villa Guardia, Italy, from First Shanghai, a financial services provider.

More... »

CenterWatch
CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs